Treatment

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.

LUNGevity's Amy Moore, PhD, sits down with Mark Awad, MD, PhD, a thoracic oncologist at Dana-Farber Cancer Institute, to discuss KRAS-positive lung cancer and what questions newly diagnosed patients should ask their doctors. We discuss first-line treatment, biomarker testing, clinical trials, and drug resistance.

On January 31, 2022,  Amy Moore, PhD, brought us an update on KRAS. Dr. Moore, LUNGevity's Vice President of Global Engagement and Patient Partnerships, spoke with Terri Conneran, KRAS lung cancer survivor and founder of the KRAS Kickers; and Darryl McConnell, PhD, Research Site Head at Boehringer Ingelheim in Vienna, Austria.

Amy Moore, PhD, LUNGevity's Vice President, Global Engagement and Patient Partnerships, conducts this webinar on ALK-positive lung cancer.

Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, interviews Patrick Forde, MD (MB, BCH), at the 2022 AACR meeting about his findings on immunotherapy in early-stage lung cancer.

April 12, 2022